Scientists track egret's 38-hour flight from Australia to PNG
A species of heron has been tracked flying for almost two days non-stop between Australia and Papua New Guinea during its northern migration, scientists say.
Australian researchers used GPS to follow eight plumed egrets and 10 great egrets over a period of months, after the birds left the Macquarie Marshes in New South Wales.
Great egrets were found to disperse in all directions, said the scientists from Australia's Commonwealth Scientific and Industrial Research Organisation.
But the plumed egrets all migrated north, and one was tracked flying almost 2,400 kilometres (1,490 miles) over several months before settling near the town of Kalo, southeast of Port Moresby.
It took that bird 38 hours to fly more than 700km across the Coral Sea, according to findings published in the journal Pacific Conservation Biology on Monday.
It was the first time scientists had recorded the plumed egrets' migration.
Another Australian bird, the bar-tailed godwit, holds the world record for flying more than 13,500 kilometres non-stop in just 11 days during its migration south from Alaska to Tasmania.
djw/bes/lb
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Medscape
an hour ago
- Medscape
Which Second-Line Therapy Is Better for Right-Sided CRC?
TOPLINE: Continuing anti-VEGF therapy plus chemotherapy in the second-line setting led to a small but nonsignificant increase in overall survival in patients with right-sided, RAS/RAF wild-type metastatic colorectal cancer (CRC) compared to patients who received anti-epidermal growth factor receptor (EGFR) therapy plus chemotherapy. METHODOLOGY: Despite limited evidence, guidelines recommend anti-EGFR therapy plus chemotherapy in the second line for patients with RAS/RAF wild-type, right-sided tumors who did not previously receive anti-EGFR therapy. To assess whether this is the best option, the current study compared the effectiveness of continuing chemotherapy plus anti-VEGF in the second-line or using anti-EGFR plus chemotherapy. Researchers used electronic health record data from 280 community oncology clinics in the US. The analysis included 444 patients (median age, 65 years) with RAS/RAF wild-type, right-sided metastatic CRC who received first-line chemotherapy plus anti-VEGF therapy, followed by second-line anti-VEGF therapy (n = 269) or anti-EGFR therapy (n = 175) with chemotherapy. Researchers then compared overall survival in these two groups. TAKEAWAY: Compared with the anti-VEGF therapy group, the anti-EGFR therapy group demonstrated a nonsignificant increased risk for death (hazard ratio [HR], 1.24; P = .10). The median overall survival was 15.3 months with anti-VEGF therapy vs 12.0 months with anti-EGFR therapy. The findings were consistent with first-line trial results, showing nonsignificant worse overall survival with anti-EGFR vs anti-VEGF therapy in right-sided tumors (HR, 1.09). IN PRACTICE: Among patients with RAS/RAF wild-type, right-sided metastatic CRC who received first-line chemotherapy plus anti-VEGF therapy, these findings 'provide some evidence for continuing anti-VEGF therapy in the second line, although the result was not statistically significant,' the authors wrote. SOURCE: This study, led by Nishwant Swami, MD, MPH, Hospital of the University of Pennsylvania, Philadelphia, was published online in JAMA Network Open. LIMITATIONS: This study was limited by possible unmeasured confounding factors and had limited statistical power due to the relatively small proportion of mCRC cases that were right-sided and RAS/RAF wild-type. DISCLOSURES: No funding information was provided for this study. Several authors reported receiving grants and personal fees and having other ties with various sources. This article was created using several editorial tools, including AI, as part of the process. Human editors reviewed this content before publication.
Yahoo
an hour ago
- Yahoo
Illuccix Approved in U.S. for Patient Selection for Pre-Taxane RLT
MELBOURNE, Australia and INDIANAPOLIS, June 23, 2025 (GLOBE NEWSWIRE) -- Telix Pharmaceuticals Limited (ASX: TLX, NASDAQ: TLX, 'Telix', 'the Company') today announces that the United States (U.S.) Food and Drug Administration (FDA) has approved a label expansion for Illuccix® (kit for the preparation of gallium Ga-68 gozetotide, for injection) to include patient selection for radioligand therapy (RLT) in the pre-taxane setting. The update applies to Illuccix's third indication, for selection of patients who are indicated for PSMA1-directed therapy as described in the Prescribing Information of the therapeutic products. The label expansion follows the FDA's approval of an expanded label for Pluvicto®2 (lutetium Lu177 vipivotide tetraxetan) for use in metastatic castration-resistant prostate cancer (mCRPC) patients after treatment with androgen receptor pathway inhibitor (ARPI) therapy and before chemotherapy3. With RLT now approved for use earlier in the patient journey, the clinical utilization of Illuccix® is expected to increase by at least 20,000 scans annually4. Scott T. Tagawa, MD, a genitourinary (GU) oncologist in New York said, 'It is pleasing to see the ability to use gallium-68 PSMA-PET for patient selection expanded. This empowers clinicians to make more informed, personalized decisions earlier in the disease course and access life-prolonging targeted radionuclide therapy for more patients with prostate cancer.' Kevin Richardson, Chief Executive Officer, Precision Medicine, Telix, said, 'We're pleased that the U.S. label for Illuccix has been expanded to support patient selection for RLT in the pre-taxane setting, aligning with the evolving treatment landscape. PSMA-PET imaging has become a standard of care in the detection and management of prostate cancer. With this update, patients can now benefit from the high diagnostic accuracy of Illuccix to identify those most likely to respond to PSMA-targeted therapy, even earlier in their treatment journey.' INDICATIONS AND USAGE Illuccix, after radiolabeling with Ga 68, is for positron emission tomography (PET) of prostate-specific membrane antigen (PSMA) positive lesions in men with prostate cancer: With suspected metastasis who are candidates for initial definitive therapy With suspected recurrence based on elevated serum prostate-specific antigen (PSA) level For selection of patients who are indicated for PSMA-directed therapy as described in the Prescribing Information of the therapeutic products IMPORTANT SAFETY INFORMATIONWARNINGS AND PRECAUTIONS Risk for MisinterpretationImage interpretation errors can occur with Illuccix PET. A negative image does not rule out the presence of prostate cancer, and a positive image does not confirm the presence of prostate cancer. Gallium Ga 68 gozetotide uptake is not specific for prostate cancer and may occur with other types of cancer as well as non-malignant processes such as Paget's disease, fibrous dysplasia, and osteophytosis. Clinical correlation, which may include histopathological evaluation of the suspected prostate cancer site, is recommended. Imaging Prior to Initial Definitive or Suspected Recurrence TherapyThe performance of Illuccix for imaging of biochemically recurrent prostate cancer seems to be affected by serum PSA levels and by site of disease. The performance of Illuccix for imaging of metastatic pelvic lymph nodes prior to initial definitive therapy seems to be affected by Gleason score. Radiation RisksGallium Ga 68 gozetotide contributes to a patient's overall long-term cumulative radiation exposure. Long-term cumulative radiation exposure is associated with an increased risk for cancer. Ensure safe handling to minimize radiation exposure to the patient and healthcare providers. Advise patients to hydrate before and after administration and to void frequently after administration. ADVERSE REACTIONSThe safety of gallium Ga 68 gozetotide was evaluated in 960 patients in the PSMA-PreRP and PSMA-BCR studies, each receiving one dose of gallium Ga 68 gozetotide. The average injected activity was 188.7 ± 40.7 MBq (5.1 ± 1.1 mCi). The most commonly reported adverse reactions were nausea, diarrhea, and dizziness, occurring at a rate of <1%.In the VISION study, 1003 patients received one dose of gallium Ga 68 gozetotide intravenously with the amount of radioactivity 167.1 ± 23.1 MBq (4.52 ± 0.62 mCi). Adverse reactions occurring at ≥0.5% in patients with metastatic prostate cancer who received gallium Ga 68 gozetotide injection in the clinical study were fatigue (1.2%), nausea (0.8%), constipation (0.5%), and vomiting (0.5%). Adverse reactions occurring at a rate of < 0.5% in the VISION study were diarrhea, dry mouth, injection site reactions, including injection site hematoma and injection site warmth and chills. DRUG INTERACTIONSAndrogen deprivation therapy and other therapies targeting the androgen pathwayAndrogen deprivation therapy (ADT) and other therapies targeting the androgen pathway, such as androgen receptor antagonists, can result in changes in uptake of gallium Ga 68 gozetotide in prostate cancer. The effect of these therapies on performance of gallium Ga 68 gozetotide PET has not been established. Please note that this information is not see the Full Prescribing Information . You are encouraged to report suspected adverse reactions of prescription drugs to the FDA. Visit MedWatch at or call 1-800-FDA-1088. You may also report adverse reactions to Telix by calling 1-844-455-8638 or emailing: pharmacovigilance@ Dr. Tagawa has served as a paid consultant to Telix and his institution has received research funding. Telix Investor Relations Ms. Kyahn WilliamsonTelix Pharmaceuticals LimitedSVP Investor Relations and Corporate CommunicationsEmail: Telix Media Relations (U.S.) Eliza Schleifstein ES Media Relations Email: eliza@ Phone: 917-763-8106 About Telix Pharmaceuticals Limited Telix is a biopharmaceutical company focused on the development and commercialization of therapeutic and diagnostic radiopharmaceuticals and associated medical technologies. Telix is headquartered in Melbourne, Australia, with international operations in the United States, Brazil, Canada, Europe (Belgium and Switzerland), and Japan. Telix is developing a portfolio of clinical and commercial stage products that aims to address significant unmet medical needs in oncology and rare diseases. Telix is listed on the Australian Securities Exchange (ASX: TLX) and the Nasdaq Global Select Market (NASDAQ: TLX). Illuccix® (kit for the preparation of gallium-68 (68Ga) gozetotide injection), Telix's first generation PSMA-PET imaging agent, is approved and commercially available in multiple countries globally. Gozellix® (kit for the preparation of gallium-68 (68Ga) gozetotide injection) has been approved by the U.S. FDA5. Visit for further information about Telix, including details of the latest share price, ASX and SEC filings, investor and analyst presentations, news releases, event details and other publications that may be of interest. You can also follow Telix on LinkedIn, X and Facebook. Legal Notices You should read this announcement together with our risk factors, as disclosed in our most recently filed reports with the Australian Securities Exchange (ASX), U.S. Securities and Exchange Commission (SEC), including our Annual Report on Form 20-F filed with the SEC, or on our website. The information contained in this announcement is not intended to be an offer for subscription, invitation or recommendation with respect to securities of Telix Pharmaceuticals Limited (Telix) in any jurisdiction, including the United States. The information and opinions contained in this announcement are subject to change without notification. To the maximum extent permitted by law, Telix disclaims any obligation or undertaking to update or revise any information or opinions contained in this announcement, including any forward-looking statements (as referred to below), whether as a result of new information, future developments, a change in expectations or assumptions, or otherwise. No representation or warranty, express or implied, is made in relation to the accuracy or completeness of the information contained or opinions expressed in the course of this announcement. This announcement may contain forward-looking statements, including within the meaning of the U.S. Private Securities Litigation Reform Act of 1995, that relate to anticipated future events, financial performance, plans, strategies or business developments. Forward-looking statements can generally be identified by the use of words such as 'may', 'expect', 'intend', 'plan', 'estimate', 'anticipate', 'believe', 'outlook', 'forecast' and 'guidance', or the negative of these words or other similar terms or expressions. Forward-looking statements involve known and unknown risks, uncertainties and other factors that may cause our actual results, levels of activity, performance or achievements to differ materially from any future results, levels of activity, performance or achievements expressed or implied by these forward-looking statements. Forward-looking statements are based on Telix's good-faith assumptions as to the financial, market, regulatory and other risks and considerations that exist and affect Telix's business and operations in the future and there can be no assurance that any of the assumptions will prove to be correct. In the context of Telix's business, forward-looking statements may include, but are not limited to, statements about: the initiation, timing, progress and results of Telix's preclinical and clinical trials, and Telix's research and development programs; Telix's ability to advance product candidates into, enrol and successfully complete, clinical studies, including multi-national clinical trials; the timing or likelihood of regulatory filings and approvals for Telix's product candidates, manufacturing activities and product marketing activities; Telix's sales, marketing and distribution and manufacturing capabilities and strategies; the commercialization of Telix's product candidates, if or when they have been approved; Telix's ability to obtain an adequate supply of raw materials at reasonable costs for its products and product candidates; estimates of Telix's expenses, future revenues and capital requirements; Telix's financial performance; developments relating to Telix's competitors and industry; the anticipated impact of U.S. and foreign tariffs and other macroeconomic conditions on Telix's business; and the pricing and reimbursement of Telix's product candidates, if and after they have been approved. Telix's actual results, performance or achievements may be materially different from those which may be expressed or implied by such statements, and the differences may be adverse. Accordingly, you should not place undue reliance on these forward-looking statements. ©2025 Telix Pharmaceuticals Limited. Telix Pharmaceuticals®, Telix Group company, and Telix product names and logos are trademarks of Telix Pharmaceuticals Limited and its affiliates – all rights reserved. Trademark registration status may vary from country to country. _________________________1 Prostate-specific membrane antigen2 Pluvicto is a registered trademark of Novartis AG and/or its affiliates.3 28 March 2025, FDA Statement: for patients who have been treated with ARPI therapy and are considered appropriate to delay taxane-based chemotherapy.4 Based on licensed indication for Pluvicto in mCRPC patients who have been treated with androgen receptor (AR) pathway inhibition.5 Telix ASX disclosure 21 March 2025.
Medscape
an hour ago
- Medscape
Do NSAIDs Affect Sacroiliitis Visibility on MRI in axSpA?
TOPLINE: Among patients with axial spondyloarthritis (axSpA) who showed active sacroiliitis on MRI after a washout of non-steroidal anti-inflammatory drugs (NSAIDs), complete resolution of MRI-visible sacroiliitis was seen in one fifth of cases, with close to half showing reduced inflammation after NSAID reintroduction. METHODOLOGY: Researchers conducted a non-randomised crossover trial across 34 centres in the UK between June 2017 and February 2020 to assess whether NSAIDs could mask active sacroiliitis on MRI in patients with axSpA. They recruited 311 patients with established or suspected axSpA and daily NSAID usage requiring sacroiliac joint MRI (median age, 42 years; 62% men; 87% White). Data on the clinical assessment were obtained. Participants underwent NSAID washout for 1-2 weeks before initial MRI (scan 1). Those who showed positive results for active sacroiliitis underwent a second scan (scan 2) at 6 weeks after resuming daily NSAIDs. Images were evaluated by two independent readers using the Leeds MRI scoring method, with scores suggesting no to severe sacroiliitis. The primary outcome was the proportion of patients with axSpA who had active sacroiliitis at scan 1 (off NSAIDs) that resolved at scan 2 after NSAIDs were reintroduced (on NSAIDs). TAKEAWAY: Among 286 patients who completed NSAID washout and underwent initial MRI, 146 showed active sacroiliitis, with follow-up scans obtained from 124 patients. Overall, 20.2% (95% CI, 13.5%-28.3%) of participants showed complete resolution of active sacroiliitis after NSAID reintroduction. Gender analysis showed no significant difference in the risk for sacroiliitis resolution between men and women. After NSAID reintroduction, 44% (95% CI, 35%-54%) of patients experienced a reduction in the Leeds score, suggesting improvement in severity. IN PRACTICE: "This provides evidence of the effect of NSAIDs on active sacroiliitis and shows that NSAID use prior to MRI may have an important impact on clinical diagnosis. Further, we show that, while patients may experience a deterioration in disease activity and spinal pain during NSAID washout, almost all patients who attempted NSAID washout were able to tolerate it. Thus, stopping NSAIDs for 1-2 weeks prior to MRI scanning in clinical practice should be considered," the authors wrote. SOURCE: This study was led by Gareth T. Jones, PhD, University of Aberdeen, Aberdeen, Scotland. It was published online on June 13, 2025, in Arthritis Care and Research. LIMITATIONS: The study protocol did not specifically state NSAID treatment, allowing participants to continue their prescribed medications and dosages. DISCLOSURES: This study received funding from Versus Arthritis. Five authors reported having financial ties, such as receiving grant support, honoraria, and consultancy, with multiple pharmaceutical companies, including AbbVie, Biogen, Eli Lilly, Novartis, Pfizer, UCB, Janssen, and others. This article was created using several editorial tools, including AI, as part of the process. Human editors reviewed this content before publication.
